Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 19.5% in the ...

Deutsche Bank says Biohaven’s (BHVN) competitor Immunovant (IMVT) reported topline data for FcRn antibody batoclimab in myasthenia gravis and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Highlights,Institutional investments in Biohaven Ltd. have shown recent increases.,The company focuses on developing ...

NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

In March 2024, InvestingPro’s Fair Value model identified Biohaven Ltd. (NYSE:BHVN) as significantly overvalued at $56.37. One year later, this analysis has proven remarkably accurate ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

The PBM plans to stop requiring coverage authorization for about 80 drugs, including Vertex’s cystic fibrosis medicines and ...

With the popular social media app once again at risk of going dark, there are best practices pharma brands can use on other ...

Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...

Scholar Rock’s spinal muscular atrophy (SMA) therapy has shown benefit in muscle function in children under 12 in a pivotal ...